Work

Estimation of Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and Mepolizumab

Year: 2019

Type: article

Source: The Journal of Allergy and Clinical Immunology In Practice

DOI: 10.1016/j.jaip.2019.09.037

Authors: Marcus Shaker, Aaron Briggs, Ahmad Dbouk, Emily Dutille, John Oppenheimer, Matthew Greenhawt

Institutions: Dartmouth College, Dartmouth–Hitchcock Medical Center, Rutgers New Jersey Medical School, Children's Hospital Colorado, University of Colorado Anschutz

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Aimmune Therapeutics, National Peanut Board, Allergy Therapeutics, European Academy of Allergy and Clinical Immunology, Agency for Healthcare Research and Quality, Genentech, Sanofi Genzyme, National Institute of Allergy and Infectious Diseases

Awards: Determining Tradeoffs Among Health Benefits, Adverse Events, and Resource Use Associated with Food Allergy Treatment, G726774268

OpenAlex ID: W2980959713

FWCI: 10.6

Cites: 10

Cited by: 58

Related to: 10